OncoSpherix News & Events
OncoSpherix Presents in the Company Showcase at the Georgia Bio Innovation Summit
OncoSpherix will launch the Company Showcase at this year's Georgia Bio Innovation Summit with a presentation entitled “Advancing Dual First-in-Class HIF-Inhibitors for Advanced Solid Cancers”. The recorded presentation will be available to registered attendees...
Kendyle Woodard joins the OncoSpherix team as Chief Operating Officer
OncoSpherix, Inc. is pleased to announce that Kendyle Woodard, MBA, is serving as Chief Operating Officer for the company. Ms. Woodard is a business operations executive with 20+ years of experience in management, marketing and...
Molecules to Medicine series
June 17, 2021: OncoSpherix’s CEO Dr. Margaret K. Offermann is scheduled to present at 1 PM ET a webinar as part of Crystal Pharma’s “Molecules to Medicine” series. The title of her presentation is “The role of collaboration in optimizing the development of HIF...
Meridian Drug Discovery Virtual Event
Margaret K Offermann, CEO of OncoSpherix, was a keynote speaker at the 2nd Meridian Drug Discovery Virtual Event. The title of her presentation was “Enhancing chemical properties of dual HIF-1 and HIF-2 inhibitors for treating advanced cancers”...
Phase 2A grant
The Georgia Research Alliance (GRA) awarded a Phase 2A grant of $53,334 to Dr. Hans Grossniklaus for studies that test OncoSpherix’s lead clinical candidate, the dual HIF inhibitor 64B, as part of combination therapy with tyrosine kinase inhibitors in mouse models of...
Kenneth Moch
Kenneth Moch joins the OncoSpherix team as Special Advisor to the CEO: “It is a privilege to have Ken Moch serve as my advisor as we build OncoSpherix into a successful drug development company that is advancing agents that should benefit patients with many types of...
Rob Scott
Robert Scott, MD, has joined the Board of Directors of OncoSpherix. Dr. Scott has held leadership positions in global Pharma for over thirty years. At Pfizer, he developed Lipitor and Norvasc. He also invented and developed the first commercially available Polypill,...
Virtual Precision in Drug Discovery & Preclinical Summit
October, 2020: OncoSpherix’s CEO, Dr. Margaret K. Offermann, served as Keynote Speaker and Session Chairperson in the Virtual Precision in Drug Discovery & Preclinical Summit. Her presentation was titled “Development of First-in-Class Small Molecule Dual HIF-1 and...
Arylsulfonamides for the Treatment of Primary and Metastatic Uveal Melanoma
OncoSpherix was awarded a $399,774 phase 1 SBIR from the NCI in for a project entitled “Arylsulfonamides for the Treatment of Primary and Metastatic Uveal Melanoma”.
Benzhydrol derivatives for the management of conditions related to hypoxia inducible factors”
US Patent entitled “Benzhydrol derivatives for the management of conditions related to hypoxia inducible factors” was awarded to Georgia State University Research Foundation and to Emory University. It is included in the portfolio that OncoSpherix licensed from the...